Wednesday, February 18, 2026 2/18/2026

Pathogenesis of Vascular Anomalies with GNAQ mutations

Award Number: R01HL167700
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/01/2024
PERIOD OF PERFORMANCE END DATE: 03/31/2028

Group Awards By:

View Award Description

Pathogenesis of Vascular Anomalies with GNAQ mutations - PROJECT SUMMARY/ ABSTRACT: Hyperactive, postzygotic mutations in the GNAQ gene (encoding for Gaq proteins) have been identified in vascular anomalies. Patients affected by this class of vascular anomalies experience extensive disfigurement and can develop a life-threatening coagulopathy termed Kasabach-Merritt Phenomenon (KMP). Despite these genetic findings, animal models for GNAQ-related vascular anomalies and KMP do not exist. This has severely hindered the preclinical development of effective targeted therapies for these patients. In our preliminary experiments we generated a transgenic murine model of mutant hyperactive GNAQ-driven vascular anomaly which recapitulates common histopathological findings in patients and a coagulopathy reminiscent of KMP, a potentially lethal disease complication. Furthermore, our studies showed that in patient- derived lesional tissue with GNAQ Q209L mutation, the MAPK/ERK signaling pathway is hyperactive as well as increased EC proliferation. We have exciting data that the MEK/ERK inhibitor Trametinib extended the life span of GNAQ mutant mice suggesting this may be a promising therapy for patients. To date there are no studies examining the role of mutant active GNAQ (p.Q209L) in vascular development and disease. This proposal will culminate with the development of innovative in vivo, in vitro, and Vessel-on-Chip models that we will use for the identification of cellular and molecular mechanisms implicated in vascular disease. Furthermore, with our powerful murine model we are uniquely positioned to develop a comprehensive research program to investigate the GNAQ role in vascular lesion formation and expansion with the goal of identifying highly needed therapeutic targets for vascular anomalies and related complications such as coagulopathies. Additionally, our studies will provide cellular and mechanistic insights to advance our understanding of pathological and physiological vessel formation and size maintenance.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $593,585 )
2025	2025	CHILDRENS HOSPITAL MEDICAL CENTER	3333 BURNET AVE	CINCINNATI	OH	45229	HAMILTON	USA	Cardiovascular Diseases Research	000	2	5/9/2025	NON-COMPETING CONTINUATION	$593,585
														Subtotal = $593,585

Issue Date FY: 2024 ( Subtotal = $608,559 )
2024	2024	CHILDRENS HOSPITAL MEDICAL CENTER	3333 BURNET AVE	CINCINNATI	OH	45229	HAMILTON	USA	Cardiovascular Diseases Research	000	1	3/28/2024	NEW	$548,780
2024	2024	CHILDRENS HOSPITAL MEDICAL CENTER	3333 BURNET AVE	CINCINNATI	OH	45229	HAMILTON	USA	Cardiovascular Diseases Research	001	1	6/10/2024	NEW	$59,779
														Subtotal = $608,559

Grand Total All Awards = $1,202,144

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Pathogenesis of Vascular Anomalies with GNAQ mutations

Award Number: R01HL167700

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/01/2024

PERIOD OF PERFORMANCE END DATE: 03/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer